Position in GRFS
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$76,995
-$75,433 QoQ
Shares Held
10,875
-42.8% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#106
of 164 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 59%
Shared 18%
None 22%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Savant Capital, LLC holds $304,795,936 across 15 Drug Manufacturers - General names. GRFS ranks #15 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
67,429 | $80,876,372 | |
| 2 | JNJ |
Johnson & Johnson
|
265,777 | $67,499,384 | |
| 3 | ABBV |
AbbVie Inc.
|
205,994 | $51,836,330 | |
| 4 | MRK |
Merck & Co., Inc.
|
220,270 | $28,304,695 | |
| 5 | NVS |
Novartis AG
|
150,968 | $23,659,704 | |
| 6 | AMGN |
Amgen Inc
|
40,234 | $14,569,536 | |
| 7 | PFE |
Pfizer Inc
|
423,589 | $10,200,023 | |
| 8 | AZN |
Astrazeneca PLC
|
35,321 | $6,697,568 |
All Filings in GRFS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $76,995 | 10,875 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $152,428 | 19,006 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $126,879 | 13,570 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $126,681 | 12,719 | Shares | Sole | 2026-03-04 | |
| 2025-06-30 | $101,121 | 11,186 | Shares | Sole | 2026-03-04 | |
| 2025-03-31 | $83,229 | 11,706 | Shares | Sole | 2026-03-04 | |
| No filing history on record for this holder in this stock. | ||||||